RGS9 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
  1. RGS9
  2. OmicsDI
  3. dbGaP

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on GitHub.

Displaying 5 of 5 results for "RGS9"

  1. RGS9-2-controlled adaptations in the striatum determine the onset of action and eficacy of antidepressants in neuropathic pain states

    ID: E-GEOD-71527

    Date Released: 08-29-2015

    Description: The striatal protein Regulator of G protein signaling-2 (

  2. Gene profiling studies in postnatal Mfrprd6 mutant eyes reveal differential expression of Prss56, a trypsin-like serine protease, and genes involved i...

    ID: E-GEOD-53411

    Date Released: 11-01-2014

    Description: he expression of RPE-specific visual transduction protein, RPE65, was significantly decreased in Mfrprd6 mutants. As an indirect consequence of the primary RPE cell defect due to the Mfrprd6 mutation, retinal specific transcripts Rgr, Pde6a, GuCa1b, and Rgs9 were also significantly decreased. We also confirmed the significantly elevated levels of Prss56, a gene previously associated with myopia and open angle glaucoma. In the Mfrprd6 mutant, a progressive increase in Prss56 mRNA levels from 14- to 70-fold was observed from P7 to P21, respectively. In situ hybridization and glutamine synthetase staining of mutant eyes indirectly identified Müller glia in the inner nuclear layer of retina as the cell type expressing the Prss56 transcript. This experiment had one model term, a combination of strain and time, which consisted of four levels (B6_P0, B6_P14, Rd6_P0 and Rd6_P14). Three biological replicates were used per term level. A total of 12 Affymetrix Mouse 430v2 Arrays were used in gene expression analysis....

  3. Identification of Differential Gene Expression During Transition of Bovine Corpus Luteum from Early To Mid–Phase.

    ID: E-GEOD-10662

    Date Released: 05-02-2014

    Description: of PGF2alpha receptors; therefore differences in signaling events might be responsible for LS. Hence differential gene expression at two developmental stages, days 4 (D-4) and 10 (D-10) post estrus, might account for differences in signal transduction pathways associated with LS. This possibility was examined in these studies. Microarray analysis (n=3 per stage) identified 167 genes that were differentially expressed (p<0.05). These were categorized into genes involved in cell signaling, steroidogenesis and metabolism, protein degrad...

  4. A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia

    ID: phs000594.v1.p1

    Description: LGL leukemia can be divided into three subsets including the following: αβ or γδT-LGL and NK-LGL leukemia. All three subtypes will...

    study.selectionCriteria: arnib previously or with other inhibitors of MAPK signaling intermediates
  5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib. Tipifarnib is contraindicated in individuals with allergies to imidazoles such as clotrimazole, ketoconazole, miconazole, econazaole, fenticonazole, isoconazole, sulconazole, tioconazole, or terconazole. Information regarding possible drug allergies should be obtained from both patient questionnaires and past-medical records
  6. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  7. Women who are pregnant
  8. Women who are breastfeeding
  9. Women of childbearing potential who will not agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  10. Men who will not agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  11. Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. HIV-positive patients receiving anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with tipifarnib, but HIV-positive patients receiving no retroviral therapy may be included in the study
  12. Patients with psychiatric illness/social situations that would limit compliance with study requirements and that would prevent informed decisions regarding entry into the study are excluded from study participation
  13. Patients with γδ T LGL that are positive for iso-chromosome 7, as determined by FISH analysis

    14. ...

  14. Effects of knockdown of ROCK1 and ZIPK on gene expression in cultured human vascular smooth muscle cells

    ID: E-GEOD-56819

    Date Released: 05-25-2015

    Description: o-associated kinase (ROCK) and zipper-interacting protein kinase (ZIPK) have been implicated in diverse physiological functions, including smooth muscle contraction, cell proliferatio...

Displaying 5 of 5 results for "RGS9"

bioCADDIE is supported by the National Institutes of Health through the Big Data to Knowledge, Grant 1U24AI117966-01. NIH | UCSD | DBMI

For more information about bioCADDIE, please visit bioCADDIE